Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 1, 2007, Pages 93-101

  Morrow, Kathleen M ^a   Fava, Joseph L ^a   Rosen, Rochelle K ^a   Vargas, Sara ^a   Barroso, Candelaria ^a   Christensen, Anna L ^a,d   Woodsong, Cynthia ^b   Severy, Lawrence ^c  

^a MIRIAM HOSPITAL   (United States)

^b RTI INTERNATIONAL   (United States)

^c FAMILY HEALTH INTERNATIONAL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HIV sexually transmitted disease protection; Instrument development; Microbicide acceptability; Pregnancy prevention; Product Characteristics; Willingness to use microbicides

Indexed keywords

MICROBICIDE;

ADULT; ARTICLE; CONDOM; CONTRACEPTION; CONTROLLED STUDY; EMPLOYMENT STATUS; EXPLORATORY RESEARCH; FEMALE; HUMAN; HYGIENE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMETRY; SCORING SYSTEM; SEXUALLY TRANSMITTED DISEASE;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; AFRICAN AMERICANS; ANTI-INFECTIVE AGENTS, LOCAL; ATTITUDE TO HEALTH; CONSUMER SATISFACTION; CONTRACEPTION BEHAVIOR; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH BEHAVIOR; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; MOTIVATION; PRINCIPAL COMPONENT ANALYSIS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEXUAL BEHAVIOR; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES; UNITED STATES; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 34247552705     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3180415ded     Document Type: Article

References (73)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2004, vol. 16. Atlanta, GA: US Department of Heath and Human Services, Centers for Disease Control and Prevention; 2005.
2. Joint United Nations Program on HIV/AIDS. Report on the Global AIDS Epidemic. Available at: http://www.unaids.org/en/HIV_data/2006GlobalReport/ default.asp. Accessed August 30, 2006.
3. Beksinska ME, Rees VH, McIntyre JA, et al. Acceptability of the female condom in different groups of women in South Africa - a multicentred study to inform the national female condom introductory strategy. S Afr Med J. 2001;91:672-678.
4. Smith LA. Partner influence on noncondom use: gender and ethnic differences. J Sex Res. 2003;40:346-350.
5. Wingood GM, DiClemente RJ. The influence of psychosocial factors, alcohol, drug use on African-American women's high-risk sexual behavior. Am J Prev Med. 1998;15:54-59.
6. World Health Organization. The Female Condom: A review. World Health Organization, Geneva, Switzerland; 1997.
7. Darroch JE, Frost JJ. Women's interest in vaginal microbicides. Fam Plann Perspect. 1999;31:16-23.
8. Holt BY, Morwitz VG, Ngo L, et al. Microbicide preference among young women in California. J Womens Health. 2006;15:281-294.
9. Francis-Chizororo M, Natshalaga NR. The female condom: acceptability and perception among rural women in Zimbabwe. Afr J Reprod Health. 2003;7:101-116.
10. Hammett TM, Mason TH, Joanis CL, et al. Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities. Sex Transm Dis. 2000;27:119-126.
11. Macaluso M, Demand M, Artz L, et al. Female condom use among women at high risk of sexually transmitted disease. Fam Plann Perspect. 2000;32:138-144.
12. Mason TH, Foster SE, Finlinson HA, et al. Perspectives related to the potential use of vaginal microbicides among drug-involved women: focus groups in three cities in the United States and Puerto Rico. AIDS Behav. 2003;7:339-351.
13. Pool R, Whitworth JA, Green G, et al. An acceptability study of female-controlled methods of protection against HIV and STDs in south-western Uganda. Int J STD AIDS. 2000;11:162-167.
14. Weeks MR, Mosack KE, Abbott M, et al. Microbicide acceptability among high-risk urban U.S. women: experiences and perceptions of sexually transmitted HIV prevention. Sex Transm Dis. 2004;31:682-690.
15. Coggins C, Elias CJ, Atisook R, et al. Women's preferences regarding the formulation of over-the-counter vaginal spermicides. AIDS. 1998;12:1389-1391.
16. Coetzee N, Blanchard K, Ellertson C, et al. Acceptability and feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides. AIDS. 2001;15:1837-1842.
17. Koo HP, Woodsong C, Dalberth BT, et al. Context of acceptability of topical microbicides: sexual relationships. J Soc Issues. 2005;61:67-93.
18. Bentley ME, Fullem AM, Tolley EE, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health. 2004;94:1159-1164.
19. Bentley ME, Morrow KM, Fullem A, et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect. 2000;32:184-188.
20. Morrow KM, Rosen R, Richter L, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health. 2003;12:655-666.
21. Rosen R, Morrow K, Carballo-Diéguez A, et al. The Acceptability of a Novel Vaginal Microbicide, PMPA Gel, Among Female Users: HPTN 050. Presented at the Microbicides 2004 Conference, March, 2004, London, England.
22. Vandebosch A, Goetghebeur E, Ramjee G, et al. Acceptability of COL-1492, a vaginal gel, among sex workers in one Asian and three African cities. Sex Transm Infect. 2004;80:241-243.
23. El-Sadr WM, Mayer KH, Maslankowski L, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006;20:1109-1116.
24. Harrison PF. Acceptability research: outcomes and future directions. The Microbicide Quarterly. 2006;4:10-12.
25. Hardy E, Jimenez AL, de Padua KS, et al. Women's preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging. Contraception. 1998;58:245-249.
26. Hira SK, Spruyt AB, Feldblum PJ, et al. Spermicide acceptability among patients at a sexually transmitted disease clinic in Zambia. Am J Public Health. 1995;85:1098-1103.
27. Raymond EG, Chen PL, Condon S, et al. Acceptability of five nonoxynol-9 spermicides. Contraception. 2005;71:438-442.
28. Hammett TM, Norton GD, Mason TH, et al. Drug-involved women as potential users of vaginal microbicides for HIV and STD prevention: a three-city survey. J Womens Health Gend Based Med. 2000;9:1071-1080.
29. Mwanza B, Siziya S, Chisembele M, et al. Dry sex and the acceptability of microbicides gel [abstract PC50]. Presented at: Microbicides 2006; 2006; Cape Town.
30. Mwanza B, Siziya S, Chisembele M, et al. Vaginal washing: a threat in evaluating microbicide effectiveness [abstract PC51]. Presented at: Microbicides 2006; 2006; Cape Town.
31. Ray S, Gumbo N, Mbizvo M. Local voices: what some Harare men say about preparation for sex. Reprod Health Matters. 1996;4:34-45.
32. Severy LJ, Newcomer S. Critical issues in contraceptive and STI acceptability research. J Soc Issues. 2005;61:45-65.
33. Ezechi O, Onwujekwe D, Odunukwe N, et al. Acceptability of vaginal microbicide among Nigerian serodiscordant couples with female negative partner [abstract PC13]. Presented at: Microbicides 2006; 2006; Cape Town.
34. Morrow K, Srikrishnan AK, Rosen R, et al. Acceptability of vaginal microbicide use in Chennai, India: a qualitative study among low- and high-risk men [abstract PC45]. Presented at: Microbicides 2006; 2006; Cape Town.
35. Oladele D, Onwuatuelo I, Adeiga A, et al. Acceptability of Savvy (C31G) gel in phase III randomized clinical trial in Lagos Nigeria [abstract PC57]. Presented at: Microbicides 2006; 2006; Cape Town.
36. Simkhada P, Simkhada B, Bhatta P. Opinions, preferences and barriers for the use vaginal microbicides by female sex workers (FSWs) in Nepal. Presented at: Microbicides 2006; 2006; Cape Town.
37. Woodsong C. Covert use of topical microbicides: implications for acceptability and use. Int Fam Plan Perspect. 2004;30:94-98.
38. Severy LJ, Spieler J. New methods of family planning: implications for intimate behavior. J Sex Res. 2000;37:258-265.
39. Biddlecom AE, Fapohunda BM. Covert contraceptive use: prevalence, motivations, and consequences. Stud Fam Plann. 1998;29:360-372.
40. Mauck CK, Weiner DH, Ballagh SA, et al. Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study. Contraception. 2004;70:77-83.
41. Mayer KH, Karim SA, Kelly C, et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS. 2003;17:321-329.
42. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543-551.
43. Coggins C, Blanchard K, Alvarez F, et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect. 2000;76:480-483.
44. Elias CJ, Coggins C, Alvarez F, et al. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Contraception. 1997;56:387-389.
45. Van Damme L, Chandeying V, Ramjee G, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS. 2000;14:85-88.
46. Schwartz JL, Mauck C, Lai JJ, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception. 2006;74:133-140.
47. Vail JG, Cohen JA, Kelly KL. Improving topical microbicide applicators for use in resource-poor settings. Am J Public Health. 2004;94:1089-1092.
48. Morrow KM, Fava JL, Rosen RK, et al. Willingness to use vaginal microbicides varies by race/ethnicity and partner type. Health Psychol. (In press).
49. Morrow KM, Vargas S, Rosen RK, et al. The utility of non-proportional quota sampling for recruiting at-risk women for microbicide research. AIDS Behav. (In press).
50. Cattell RB. The Scree Test for the number of factors. Multivariate Behav Res. 1966;1:245-276.
51. Velicer WF. Determining the number of components from the matrix of partial correlations. Psychometrika. 1976;41:321-327.
52. Horn JL. A rationale and test for the number of factors in factor analysis. Psychometrika. 1965;30:179-185.
53. O'Connor BP. SPSS and SAS programs for determining the number of components using parallel analysis and Velicer's MAP test. Behav Res Methods Instrum Comput. 2000;32:396-402.
54. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297-334.
55. LISREL 8.7 for Windows [computer program]. Lincolnwood, IL: Scientific Software International; 2004.
56. Bentler PM. Comparative fit indexes in structural equation models. Psychol Bull. 1990;107:238-246.
57. Tucker LR, Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika. 1973;38:1-10.
58. Bentler PM. EQS: A Structural Equations Program. Los Angeles, CA: BMDP Statistical Software; 1989.
59. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Structural Equation Modeling. 1999;6:1-55.
60. Zierler S, Krieger N. Reframing women's risk: social inequalities and HIV infection. Annu Rev Public Health. 1997;18:401-436.
61. Sikkema KJ, Heckman TG, Kelly JA, et al. HIV risk behaviors among women living in low-income, inner-city housing developments. Am J Public Health. 1996;86:1123-1128.
62. Grimley DM, Annang L, Lewis I, et al. Sexually transmitted infections among urban shelter clients. Sex Transm Dis. 2006;33:666-669.
63. Chan DJ. Factors affecting sexual transmission of HIV-1: current evidence and implications for prevention. Current HIV Research. 2005;3:223-241.
64. Risbud A. Human immunodeficiency virus (HIV) and sexually transmitted diseases (STDs). Indian J Med Res. 2005;121:369-376.
65. Bond L, Semaan S. At risk for HIV infection: incarcerated women in a county jail in Philadelphia. Women Health. 1996;24:27-45.
66. Hallfors DD, Iritani BJ, Miller WC, et al. Sexual and drug behavior patterns and HIV and STD racial disparities: the need for new directions. Am J Public Health. 2007;97:125-132.
67. Annang L, Grimley DM, Hook EW 3rd. Vaginal douche practices among black women at risk: exploring douching prevalence, reasons for douching, and sexually transmitted disease infection. Sex Transm Dis. 2006;33:215-219.
68. Steptoe A, Pollard TM, Wardle J. Development of a measure of the motives underlying the selection of food: the food choice questionnaire. Appetite. 1995;25:267-284.
69. Andrews RL, Currim IS. Identifying segments with identical choice behaviors across product categories: an intercategory logit mixture model. Int J Res Mark. 2002;19:65-79.
70. Galavotti C, Cabral RJ, Lansky A, et al. Validation of measures of condom and other contraceptive use among women at high risk for HIV infection and unintended pregnancy. Health Psychol. 1995;14:570-578.
71. Grimley DM, Riley GE, Bellis JM, et al. Assessing the stages of change and decision-making for contraceptive use for the prevention of pregnancy, sexually transmitted diseases, and acquired immunodeficiency syndrome. Health Educ Q. 1993;20:455-470.
72. Highstein GR, Willey C, Mundy LM. Development of stage of readiness and decisional balance instruments: tools to enhance clinical decision-making for adherence to antiretroviral therapy. AIDS Behav. 2006;10:563-573.
73. Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol. 1994;13:39-46.